Despite the encouraging results with enzyme replacement therapy for several lysosomal storage diseases (LSDs), successful delivery of enzyme to brain to correct central nervous system (CNS) storage has been an elusive target (Grubb et al, 2010). In that regard, the paper by Sorrentino et al (2013) in this issue is a major breakthrough. It is likely to generate widespread interest and have a large impact on research in the field.

Why is this work so important? Most of the LSDs have some element of CNS involvement. In many of them, like Sanfilippo disease type IIIA, CNS involvement is the dominant feature (Rozaklis et al, 2011). Correction of this aspect of LSDs that profoundly affects brain and leads to progressive neurological deterioration has posed the greatest challenge. Successfully meeting that challenge is a big deal!

Access of corrective enzyme to lysosomes in cells of most tissues relies on receptor-mediated endocytosis, by the ubiquitously expressed mannose-6-phosphate (Man-6-P) receptor and mannose receptors on cells of the macrophage lineage. Cells in the CNS have limited access to enzymes targeting these receptors. Indeed, the blood–brain barrier (BBB) effectively blocks access of such proteins except in the perinatal period. In the mouse, access to Man-6-P receptors on the brain capillaries is limited to the first 2 weeks of life, after which the brain becomes very resistant to infused native enzyme (Urayama et al, 2008). For this reason, effective clearance of established CNS storage by infused enzymes has been quite limited.

More invasive approaches involving direct injection of enzyme into the cerebrospinal fluid intrathecally, or into the brain itself, have shown promise (Fraldi et al, 2007). In fact, clinical trials are underway to evaluate intrathecal therapy. In urgent situations like spinal cord compression, such aggressive measures are acceptable. However, more widespread application in humans may be impractical.

Some success in delivering enzyme to brain with conventional enzyme therapy, but in higher than conventional doses, has been obtained in several animal models (Vogler et al, 2005). In most cases, the correction was limited. These studies suggested that prolonged exposure to circulating enzyme, whether achieved by repeatedly infusing large doses, or by chemically modifying the enzyme to delay its clearance, enhanced the likelihood of neuronal correction. What appeared to be a significant advance in extending the circulating lifetime of β-glucuronidase by chemical modification and enhancing CNS correction in the adult mouse model of mucopolysaccharidosis (MPS) VII (Grubb et al, 2010) proved not to be useful in the murine models of MPS IIIA (Rozaklis et al, 2011) and juvenile neuronal ceroid lipofuscinosis (Batten disease) (Meng et al, 2012). These diseases and many others like them still need a breakthrough.

Sorrentino et al (2013) improved on their own prior work and that of others using several clever strategies. They chose the well-characterized murine model for MPS IIIA (Sanfilippo type IIIA). This naturally occurring mouse model has progressive neurological disease due to deficiency of sulphamidase (SGSH) which results in inability to degrade heparan sulphate in the CNS. The pathophysiology and predictable course had been very well defined by Rozaklis et al (2011), who showed that the CNS storage was resistant...
to even large doses of infused native or chemically modified SGSH.

Sorrentino et al. (2013) reasoned they might deliver enzyme by transcytosis, targeting a receptor that delivers an essential nutrient across the BBB. Transcytosis involves endocytosis at one cell surface (e.g. apical) followed rapidly by exocytosis at the opposite cell surface (e.g. basolateral) without delivery to lysosomes. Candidate receptors include the transferrin receptor, the insulin-like growth factor receptor, and the LDL receptor (LDLR), each of which has been targeted in other work to deliver chimeric proteins to brain. Usually an antibody to the relevant receptor was used as a ‘Trojan horse’ to carry the desired protein across brain capillary endothelial cells (Zhou et al, 2012).

Spencer and Verma (2007) had successfully targeted the LDLR to deliver a virally expressed lysosomal enzyme to brain, providing proof of principle. Although correction of storage was not studied, they subsequently used this approach to deliver the protease nephrilysin to brain in a transgenic Alzheimer mouse model. They showed not only efficacy in reducing brain accumulation of amyloid-beta peptide, but also improvement in CNS function (Spencer et al, 2008).

Following a similar strategy, Sorrentino et al. (2013) produced a chimeric SGSH enzyme with a C-terminal extension comprising the LDLR binding domain from apolipoprotein B. As a novel twist, they substituted the signal sequence from another acid hydrolase, iduronate sulphatase (IDS), which they demonstrated by the AAV2/8 signal sequence was confirmed (serum levels seven- to nine-fold higher). The secreted enzyme was shown to be targeted to lysosomes of mouse embryo fibroblasts in vitro not only by the Man-6-P receptor, but also by an endocytosis receptor which appeared to recognize the apo B domain in the chimeric enzyme, as predicted. Delivery to brain and uptake by both neurons and astrocytes was demonstrated convincingly. In addition, neuropathology and glycosaminoglycan (GAG) storage in brain were corrected. Biomarkers for increased inflammation and aberrant autophagy that typically accompany GAG storage in brain were normalized. Finally, behavioural abnormalities were also corrected. The females, which typically become hyperactive in this model, calmed down; the males, which typically become sluggish, perked up with treatment. The appropriate controls showed that the apo B tag was required for these therapeutic responses. AAV2/8 expressing the enzyme with or without the IDS signal sequence but without the apo B tag was not effective.

All in all, it’s quite a complete and remarkable story. Still, some questions remain. Are we certain that the apo B targets receptors on the BBB and promotes transcytosis across the BBB? Although this seems a plausible interpretation, could it be targeting some cells in the macrophage lineage that are recruited to brain and deliver enzyme by this route? Such cell-mediated delivery is thought to explain the CNS correction following haematopoietic stem cell replacement (Biffi et al, 2006). Is sustained high-level expression required, or could this exciting success be translated to conventional enzyme replacement therapy, where weekly or biweekly infusions are typical and brain capillaries are exposed to high levels only briefly?

Whatever the mechanism of this extraordinary CNS correction, it is likely that many laboratories will try to replicate these studies with AAV vectors expressing enzymes missing in other lysosomal diseases affecting brain (Krabbe disease, Batten disease, Tay-Sachs disease and many others). In all of these, delivery of enzymes across the BBB to correct CNS pathology and prevent the devastating cognitive impairment is the major unmet need.

Acknowledgements
WSS and CV are both supported by National Institutes of Health grant GM034182.

The authors declare that they have no conflict of interest.

References
Biffi A, Capotondo A, Fasano S, del Carro U, Marchesini S, Azuma H, Malaguti MC, Amadio S, Brambilla R, Grompe M, et al (2006) Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J Clin Invest 116: 3070-3082
Fradl D, Hemsley K, Crawley A, Lombardi A, Lau A, Sutherland L, Auriolchiro A, Ballabio A, Hopwood JJ (2007) Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. Hum Mol Genet 16: 2693-2702
Grubb JH, Vogler C, Sly WS (2010) New strategies for enzyme replacement therapy for lysosomal storage diseases. Rejuvenation Res 13: 229-236
Meng Y, Sohar I, Wang L, Sleat DE, Lobel P (2012) Systemic administration of tripeptidyl peptidase I in a mouse model of late infantile neuronal ceroid lipofuscinosis: effect of glycan modification. PLoS ONE 7: e40509
Rozakis T, Beard H, Hassiotis S, Garcia AR, Tonini M, Luck A, Pan J, Lamsa JC, Hopwood JJ, Hemsley
Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA. Exp Neurol 230: 123-130

Sorrentino NC, D’Orsi L, Sambri I, Nusco E, Monaco C, Spampanato C, Polishchuk E, Saccone P, De Leonibus E, Ballabio A et al (2013) A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA. EMBO Mol Med 5: 675-690

Spencer B, Marr RA, Rockenstein E, Crews L, Adame A, Potkar R, Patrick C, Gage FH, Verma IM, Masliah E (2008) Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice. BMC Neurosci 9: 109

Spencer BJ, Verma IM (2007) Targeted delivery of proteins across the blood-brain barrier. Proc Natl Acad Sci USA 104: 7594-7599

Urayama A, Grubb JH, Sly WS, Banks WA (2008) Mannose 6-phosphate receptor-mediated transport of sulfamidase across the blood-brain barrier in the newborn mouse. Mol Ther 16: 1261-1266

Vogler C, Levy B, Grubb JH, Calvin N, Tan Y, Kakisis E, Pavloff N, Sly WS (2005) Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA 102: 14777-14782

Zhou QH, Boado RJ, Pardridge WM (2012) Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies. J Drug Target 20: 715-719